Overview

* ImmunityBio Q3 2025 product revenue up 434% yr/yr, driven by ANKTIVA demand

* Company's cash position rose to $257.8 mln as of September 30, 2025

Outlook

* ImmunityBio ( IBRX ) did not provide specific financial guidance for future quarters or the full year

Result Drivers

* ANKTIVA DEMAND - Strong demand for ANKTIVA in NMIBC CIS drives 434% increase in product revenue, per CEO Richard Adcock

* CASH POSITION - Cash, cash equivalents, and marketable securities rose to $257.8 mln as of September 30, 2025

*

Research and development (R&D) expense increased $0.8 million to $51.2 million during the three months ended September 30, 2025, as compared to $50.4 million during the three months ended September 30, 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$67.27

Income mln

Q3 -$55.63

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Immunitybio Inc ( IBRX ) is $8.00, about 74% above its November 4 closing price of $2.08

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)